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Cerebral palsy has an incidence of about 1-2 per 1000 live births, and in spite of the 
progress of neonatal medicine, it seems that the incidence will not subside in the near 
future. The most important characteristic of cerebral palsy is movement abnormality: 
spasticity, chorea, athetosis, ataxia, dystonia, as well as their different combinations. 
About 70% of children who suffer from cerebral palsy also suffer from some form of 
spasticity. Spasticity is a type of muscle hypertonicity characterized by rapid increase in 
resistance to passive stretching of muscles. The interest for botulinum toxin application 
in the treatment of spasticity has dramatically increased in the last 10 years. Botulinum 
toxin is the most powerful neurotoxin that is found in nature. It is produced by anaerobic 
bacteria – clostridium botulinum. It is produced in eight serotypes of which type A is the 
most commonly used. Botulinum toxin blocks neuromuscular transmission and causes 
irreversible weakness of the treated muscle. It has been used since 1993 in the 
treatment of cerebral palsy in children. The toxin effect is permanent and it results in 
irreversible denervation. Functional recovery is possible after 2-4 months, due to 
sprouting of nerve endings and the formation of new synaptic contacts. Treatment with 
botulinum toxin is safe. Adverse effects are rare, temporary and completely reversible. 
Application of botulinum toxin prevents or reduces contractures and deformities, and 
t h u s  d e l a y s  o r  a v o i d s  s u r g i c a l  t r e a t m e n t .  Y e t ,  p h y s i c a l  t h e r a p y ,  w h i c h  p r o l o n g s  a n d  
improves the effects of botulinum toxin, remains an essential and most important form 
of therapy in the treatment of children with cerebral palsy. Acta Medica Medianae 
2011;50(2):63-67. 
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Introduction 
 
Cerebral palsy has an incidence of about 1-
2 per 1000 live births, and in spite of the 
progress of neonatal medicine, it seems that the 
incidence will not subside in the near future. 
There are numerous definitions of the cerebral 
palsy, but not one of them is completly adequate 
and comprehensive. Most definitions highlight: 
the relative persistence of state and pre-
dominantly motor problems (problems of posture 
and movement), which is a result of early (pre-, 
peri-, and post-natal) brain damage. Often, in 
addition to motor problems, a number of 
associated disorders are present (slow mental 
development, mental disorders, problems with 
vision, hearing, speech, epilepsy, etc.). 
The most important characteristic of 
cerebral palsy is the movement abnormality: 
spasticity, chorea, athetosis, ataxia, dystonia, as 
well as their different combinations. 
 
Pathophysiology of cerebral spasticity 
 
Muscle tone is regulated by α motor neuron 
in the spinal cord, and it is normal when there is 
a balance between the two competitive forces. 
Those forces are: 
- Excitatory impulses are generated in the 
muscle spindle and Golgi tendon organ then they 
enter the spinal cord through afferent neuron and 
release excitatory neurotransmitters such as 
glutamate and aspartate. 
-  Inhibitory impulses arise in the basal 
ganglia, brain stem and cerebellum, then go 
down the spinal cord and release the inhibitory 
neurotransmitter - γ-aminobutyric acid (GABA) 
from interneurons, which then connects to the α 
motor neuron (1). 
In cerebral palsy, part of the brain that 
produces descending inhibitory impulses is 
damaged, resulting in the relative "excess" of 
excitatory impulses and increase in muscle tone. 
Spasticity is a type of muscle hypertonicity 
characterized by rapid increase in resistance to 
passive stretching of the muscles. It is often 
accompanied by weakness, hyperreflexia and 
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clonus. It is present when a person is awake, but 
it decreases when a person is asleep. It increases 
with excitement and with voluntary movements 
when also simultaneous contractions of the 
antagonist occur. All this results in a movement 
that is stiff, jerky and imprecise.  
Spasticity more often attacks lower in 
relation to the upper limbs. It also more often 
attacks flexors, adductors and internal rotators 
than their antagonists. Around 60 – 70 % of 
children who suffer from cerebral palsy, also 
suffer from spasticity, and usually in combination 
with some other disorder - chorea, athetosis, 
dystonia. The degree of spasticity varies from 
medium to heavy, which is, in practice, classified 
according to the Ashworth scale. 
Treatment of these children is reduced to 
physical medicine and rehabilitation, orthopedical 
treatment and application of orthotic devices, in 
order to prevent or treat existing structural 
defects that occur secondarily because of the 
presence of neurological lesions (2). Child that 
will later develop cerebral palsy does not have 
any deformities or contractures at birth. As child 
grows and develops, spastic musculature cannot 
follow the growth of the surrounding structures 
and tissues. That leads to contractures, defor-
mities and damaged functions. The primary 
cause of the shortening of the muscle is 
hypertonia which is always present and long-
lasting. In contrast, passive stretching of a 
relaxed muscle can restore the normal 
longitudinal growth (3). 
In the last decades, great efforts have been 
m a d e  t o  f i n d  a n  a d e q u a t e  r e m e d y  t o  r e d u c e  
spasticity. Application of that remedy should 
relax the over-active muscles. Medications for 
spasticity reduction that can be applied orally 
are: baclofen, diazepam and dantrolen. Their 
application did not show the expected results. 
When applied in the usual therapeutic dosage, 
the minimal reduction in spasticity is achieved. If 
the dosage is increased, the side effects occur 
(lethargy, drowsiness), and even hepatotoxicity 
with dantrolen (4). Slightly better effects are 
obtained by intrathecal application of baclofen, 
and by selective posterior rhizotomy (5). 
In the last ten years, interest in the 
application of botulinum toxin in treating 
spasticity has sharply increased. Great number of 
studies shows positive therapeutic effects of 
botulinum toxin, with negligible side effects.  
Botulinum toxin is the most powerful 
neurotoxin that is found in nature. It is produced 
by anaerobic bacteria – clostridium botulinum. A 
very small amount of the toxin leads to botulism 
– paralysis with bulbar symptoms, and affects 
the autonomic nervous system.  
 
History 
 
Botulism was registered in 1822. Back then 
it was thought to occur as a result of poisoning 
by fatty acids from sausages. In 1897, van 
Ermengem proved that it was a bacterial toxin.  
In a randomized, controlled study, done on 
an animal model, it was proven that botulinum 
toxin A leads to decrease of spasms, and in that 
way prevents contractures with hereditary spastic 
mice. 
The discovery that botulinum toxin can 
block neuromuscular transmission and cause 
muscle weakness became the basis of numerous 
studies for the use of toxin in therapeutic 
purposes. 
Alan Scott, ophthalmologist, was the first 
one to use botulinum toxin for strabismus 
treatment in 1981. After that, there was an 
expansion of research in various medical fields. 
Toxin is used in treatment of various diseases: 
multiple sclerosis, stroke, Parkinson's disease, 
tremor (essential, cerebellar, etc.), dystonia, 
myofascial pain syndrome, hemifacial spasm, 
spasmodic torticollis, migraine, blepharospasm, 
laryngeal disorders, hypertension m. masseter, 
the anal fissure, hyperhidrosis, in cosmetics, etc. 
Botulinum toxin was first used in the 
treatment of spasticity in children with cerebral 
palsy in 1993. The most common indication is 
spastic equinus feet. 
 
Mechanism of action  
 
Bacteria Clostridium botulinum produces 
eight serotypes of toxin (A, B, C1, C2, D, E, F 
and G). Type A is mostly used in human 
medicine. They all have similar structure and 
molecular mass, and they consist of a heavy (H) 
and light (L) chains that are linked by disulfide 
bond. Botulinum toxin accumulates in the 
synaptic end of the cholinergic neuron during the 
specific process, called endocytosis. After the 
splitting of the disulfide bond, it separates into 
two polypeptide chains, and the light one gets 
the endopeptidase activity. Substrate for the light 
chain is a cytoplasmic protein SNAP 25 (SyNapto-
somal Associated Protein), involved in the 
exocytosis of synaptic vesicles. Splitting of this 
protein disables further release of acetylcholine. 
Mechanism of action is shown in Picture 1. The 
effect of the toxin is permanent and it results in 
irreversible denervation. Functional recovery is 
possible after 2-4 months, due to sprouting of 
nerve endings and the formation of new synaptic 
contacts (6). 
 
Application of botulinum toxin in 
cerebral palsy treatment 
 
Botulinum toxin is used with children with 
cerebral palsy, with a goal to reduce spasticity, 
increase the range of motions and improve 
function (7). It is most commonly administered in 
the lower extremities and in m. gastrocnemius in 
the case of dynamic spasticity of equinus feet. If 
there is a fixed deformity, the use of the toxin is 
not indicated. Botulinum toxin is also often 
applied in adductors and muscles of the thigh, 
while the application in upper limb muscles is 
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Picture 1. Schematic illustration of the mechanism of action of botulinum toxin, type A 
 
Botulinum toxin is used in children aged 2-
6. Toxin dosage is determined by the weight of a 
child. The usual dosage is 10units/kg if the toxin 
is applied in one leg or 20units/kg if it is applied 
in both legs. The maximum dose must not 
exceed 30units/kg. This dosage is applied with 
DYSPORT (Ipsen). If another preparation is used 
(BOTOX), the dosage is different, that is, the 
units of these two preparations are not 
comparable and cannot be mathematically 
converted from one to another (8). 
In routine clinical practice, the site for 
injecting the preparation is determined by 
palpation. In the case of small muscles (upper 
extremities), EMG “guidance” is necessary (7). 
In most cases, botulinum toxin is applied 
without sedation and anesthesia. Four to five 
days after application, it is necessary to start an 
intensive physical therapy and to use the 
orthotics (9, 10). 
Before the treatment, three weeks after, as 
well as 3, 6 and 12 months after the treatment, it 
is necessary to conduct the appropriate checks 
and measurements, so that the results would be 
recorded and monitored. Things usually done 
are: measuring the spasticity according to the 
modified Ashworth’s scale, measuring the range 
of movement using the standard goniometer, 
function assessment (using the suitable valid 
scale for assessment of the motor status), 
subjective assessment by parents and child. The 
most prominent therapeutic effect is evident after 
two to three weeks, the tone reduction is 
registered (in average 2-3 levels on Ashworth’s 
scale), range of motion is increased (in average 
7-15 degrees for dorsiflexion in the ankle), 
plantar surface during standing is increased, and 
there is also an improvement in the walking 
speed, covered distance and the stride length. 
The effects last from two to four months and 
after that the application can be repeated 
(usually botulinum toxin can be applied once, 
twice or three times). 
The botulinum toxin therapy is safe and 
secure. Side effects are rare, transient, local and 
completely reversible (11-13). The frequency of 
side effects after administration of botulinum 
toxin A (Dysport) was determined based on three 
prospective studies with 142 patients and 75 
patients in the placebo group. Side effects with 
an incidence greater than 5% were: pain in the 
leg 8%, pharyngitis 8%, accidental injury 7%, 
bronchitis 6% and fever 6%. Side effects with an 
incidence 1-5% were: viral infection 5%, infection 
4%, rhinitis 4%, convulsions 4%, infections of the 
upper respiratory tract 4%, asthenia 3%, asthma 
3%, cough 3%, vomiting 3%, colds 2%, diarrhea 
2%, unbalanced walk 1%, gastroenteritis 1%, 
laryngitis 1% and somnolence 1%. 
Many of these effects (pharyngitis, bronchitis, 
fever, viral infection, rhinitis, infections of the 
upper respiratory tract, cough, vomiting and flu) 
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had a similar incidence in the placebo group, 
corresponding to the typical spectrum of diseases 
in the pediatric population. In addition, the 
frequency of seizures was identical with the 
placebo group, which is consistent with the 
frequent presence of this problem in cerebral 
palsy. The only significant difference with the 
placebo group (1%) was with the accidental 
injuries (falls). This side effect is probably due to 
excessive weakening of the treated muscle and / 
or due to local distribution of the preparation to 
other muscles important for walking. Pain in the 
leg after application in the placebo group, was 
present in 5% of the patient. Asthenia and 
urinary incontinence were associated with higher 
doses of Dysport (30 units) and could be due to 
systemic spread of the toxin. 
 
Conclusion 
 
Botulinum toxin, type A treatment of the 
cerebral palsy in children is an effective and safe 
way to reduce spasticity and increase mobility. 
Early treatment of spasticity prevents the 
occurrence of contractures and deformities, and 
hence the need for surgical treatment is delayed 
or even avoided. Comprehensive physical therapy 
definitely has an important and indispensable role 
in that prolonging and enhancing the effects of 
the botulinum toxin A. 
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PRIMENA BOTULINSKOG TOKSINA TIP A U TRETMANU 
SPASTICITETA I KOD DECE SA CEREBRALNOM PARALIZOM 
 
Ljiljana Lazić, Hristina Čolović, Olga Marinković, Marija Spalević, Anita Stanković i Dragan Zlatanović 
 
 
  Cerebralna paraliza se javlja sa incidencom od oko 1-2 na 1000 živorođenih. Uprkos 
napretku neonatalne medicine, izgleda da incidenca neće opasti u bližoj budućnosti. 
Najvažnija karakteristika cerebralne paralize jeste abnormalnost pokreta: spasticitet, 
horea, atetoza, distonija, ataksija ili njihove različite kombinacije. Oko 70% dece sa 
cerebralnom paralizom ima spasticitet. Spasticitet je tip mišićne hipertonije koji se 
karakteriše brzim porastom otpora na pasivno istezanje mišića. U poslednjih 10 godina 
naglo je poraslo interesovanje za primenu toksina botulina u lečenju spasticiteta. Botulin 
toksin je najmoćniji neurotoksin koji se nalazi u prirodi. Produkuje ga anaerobna 
bakterija clostridium botulinum u 8 serotipova, od kojih se najčešće koristi tip A. Botulin 
toksin blokira neuromišićnu transmisiju i izaziva ireverzibilnu slabost tretiranog mišića. 
Funkcionalni oporavak je moguć nakon 2-4 meseca zbog prorastanja nervnih završetaka 
i formiranja novih sinaptičkih kontakata. Najčešća indikacija za primenu kod dece sa 
cerebralnom paralizom je spastični pes equinus. Primenom toksina botulina sprečava se 
ili ublažava pojava kontraktura i deformacija, a time se odlaže ili izbegava operativni 
zahvat. Neželjeni efekti su retki, prolazni i reverzibilni. Ipak, fizikalni tretman ostaje 
nezaobilazan i najvažniji vid terapije u tretmanu dece sa cerebralnom paralizom. Acta 
Medica Medianae 2011;50(2):63-67. 
 
Ključne reči: cerebralna paraliza, spasticitet, botulin toksin, deca 
 